

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



LSHTM Research Online

Westermann, D; Goodman, SG; Nicolau, JC; Requena, G; Maguire, A; Chen, JY; Granger, CB; Grieve, R; Pocock, SJ; Blankenberg, S; +5 more... Vega, AM; Yasuda, S; Simon, T; Brieger, D; TIGRIS Study Investigators; (2017) Rationale and design of the long-Term risk, clinical management, and healthcare Resource utilization of stable coronary artery disease in post-myocardial infarction patients (TIGRIS) study. *Clinical cardiology*. ISSN 0160-9289 DOI: <https://doi.org/10.1002/clc.22837>

Downloaded from: <http://researchonline.lshtm.ac.uk/4646009/>

DOI: <https://doi.org/10.1002/clc.22837>

**Usage Guidelines:**

Please refer to usage guidelines at <https://researchonline.lshtm.ac.uk/policies.html> or alternatively contact [researchonline@lshtm.ac.uk](mailto:researchonline@lshtm.ac.uk).

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

<https://researchonline.lshtm.ac.uk>



**Rationale and design of the “long-Term rIsk, clinical  
manaGement and healthcare Resource utilization of stable  
coronary artery dISEase in post myocardial infarction  
patients” (TIGRIS) study**

Journal:	<i>Clinical Cardiology</i>
Manuscript ID	CLC-17-0517
Wiley - Manuscript type:	Clinical Investigations
Date Submitted by the Author:	17-Jul-2017
Complete List of Authors:	<p>Blankenberg, Stefan; Universitäres Herzzentrum Hamburg, Klinik für Allgemeine und Interventionelle Kardiologie            Westermann, Dirk; University Heart Center Eppendorf, Department of General and Interventional            Goodman, Shaun; University of Toronto, Canadian Heart Research Centre; St Michael's Hospital, Div of Cardiology            Nicolau, Jose; Heart Institute (InCor) - University of São Paulo Medical School, Cardio pneumology            Requena , Gema ; Oxon Epidemiology SL, Oxon Epidemiology            Maguire, Andrew; Oxon Epidemiology SL, Oxon Epidemiology            Chen, Ji-yan; Guangdong Cardiovascular Institute, Department of Cardiology            Granger, Christopher; Duke Clinical Research Institute, Duke University Medical Center            Grieve, Richard; London School of Hygiene and Tropical Medicine, London School of Hygiene and Tropical Medicine            Pocock, Stuart J.; Medical Statistics Department, London School of Hygiene and Tropical Medicine, London, England, Medical Statistics            Vega, Ana; AstraZeneca, Medical Evidence and Observational Research, Global Medical Affairs            Yasuda , Satoshi ; Kokuritsu Junkankibyō Kenkyū Center, National Cerebral and Cardiovascular Center            Simon, Tabassome; UPMC-Paris 06 University, Assistance Publique-Hopitaux de Paris (APHP)            Brieger, David; Concord Hospital and University of Sydney, Concord Hospital and University of Sydney</p>
Keywords:	Coronary artery disease, Healthcare resource utilization, Observational, Trial design, Myocardial infarction

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

SCHOLARONE™  
Manuscripts

For Peer Review

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Rationale and design of the “long-Term risk, clinical management and healthcare Resource utilization of stable coronary artery disease in post myocardial infarction patients” (TIGRIS) study

Stefan Blankenberg MD<sup>1,2</sup>, Dirk Westermann MD<sup>1,2</sup>, Shaun G. Goodman MD, MSc<sup>3</sup>,  
Jose C. Nicolau MD, PhD<sup>4</sup>, Gema Requena PharmD, MPH, PhD<sup>5</sup>, Andrew Maguire  
PhD<sup>5</sup>, Ji Yan Chen MD<sup>6</sup>, Christopher B Granger MD<sup>7</sup>, Richard Grieve PhD<sup>8</sup>, Stuart J.  
Pocock PhD<sup>8</sup>, Ana Maria Vega MD<sup>9</sup>, Satoshi Yasuda MD, PhD<sup>10</sup>, Tabassome Simon  
MD, PhD<sup>11</sup>, David Brieger MD, PhD<sup>12</sup>, for the TIGRIS Study Investigators

*<sup>1</sup>Department of General and Interventional, University Heart Center Eppendorf,  
Hamburg, Germany; <sup>2</sup>German Center for Cardiovascular Research (DZHK), Partner  
site Hamburg/Lübeck/Kiel, Hamburg, Germany; <sup>3</sup>Terrence Donnelly Heart Centre, St  
Michael's Hospital, University of Toronto, Toronto, Canada; <sup>4</sup>Heart Institute (InCor),  
University of São Paulo Medical School, São Paulo, Brazil; <sup>5</sup>Oxon Epidemiology  
(UK), London, UK; <sup>6</sup>Guangdong General Hospital, Provincial Key Laboratory of  
Coronary Disease, Guangzhou, China; <sup>7</sup>Duke Clinical Research Institute, Duke  
University Medical Center, Durham, USA; <sup>8</sup>London School of Hygiene and Tropical  
Medicine, London, UK; <sup>9</sup>Medical Evidence and Observational Research, Global  
Medical Affairs, AstraZeneca, Madrid, Spain; <sup>10</sup>National Cerebral and Cardiovascular  
Center, Osaka, Japan; <sup>11</sup>Assistance Publique-Hopitaux de Paris (APHP), UPMC-  
Paris 06 University, Paris, France; <sup>12</sup>Concord Hospital and University of Sydney,  
Sydney, Australia*

Corresponding author: Dirk Westermann, Department of General and Interventional,  
University Heart Center Eppendorf, 20246 Hamburg, Germany.

Email: d.westermann@uke.de

Tel: +49 (0) 40 7410 - 53979

**Word count:** 2739 (max 3000)

**Short title:** Rationale and design of the TIGRIS study

## Disclosures

Stefan Blankenberg	Speaker/consulting honoraria and/or research grant support from Abbott, Abbott Diagnostics, AstraZeneca, Bayer, Boehringer Ingelheim, Medtronic, Novartis, Pfizer, Roche, Siemens, Siemens Diagnostics, Thermo Fisher
Dirk Westermann	Speaker/consulting honoraria and/or research grant support from AstraZeneca, Bayer, Berlin-Chemie, Biotronik, Novartis
Shaun G. Goodman	Speaker/consulting honoraria and/or research grant support from Amgen Inc., Amilyn, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Ferring Pharmaceuticals, GlaxoSmithKline, Matrizyme, Merck, Novartis, Pfizer, Regeneron, Revalerio, Sanofi, Servier, Tenax Pharmaceuticals
Jose C. Nicolau	Speaker/consulting honoraria and/or research grant support from Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, GSK, Merck, Novartis, Pfizer, Sanofi
Gema Requena	Employed by OXON Epidemiology Ltd (which has received funding from AstraZeneca)
Andrew Maguire	Employed by OXON Epidemiology Ltd (which has received funding from AstraZeneca)
Ji Yan Chen	None
Christopher B Granger	Consulting honoraria and/or research grant support from Armethion, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo Eli Lilly, Gilead, Glaxo SmithKline, Hoffmann-La Roche, Janssen Pharmaceuticals,

	Metronic, Pfizer, Salix Pharmaceuticals, Sanofi, Takeda, The Medicines Company
Richard Grieve	None
Stuart Pocock	Statistical consulting honoraria from AstraZeneca
Tabassome Simon	Speaker/consulting honoraria and/or research grant support from Astellas, Amgen Inc., AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, Sanofi
Satoshi Yasuda	Speaker/consulting honoraria and/or research grant support from Takeda, Daiichi-Sankyo, Astra-Zeneca, Boehringer Ingel, Bristol-Myers
Ana Maria Vega	Employed by AstraZeneca
David Brieger	Speaker/consulting honoraria and/or research grant support from Amgen Inc., AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Merck, Sanofi

### Role of the funding source

The long-Term rlsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) study is supported by AstraZeneca AB, Södertälje, Sweden. The sponsor was involved in the study conception and design, data collection, interpretation of the data and review of the manuscript. The authors and other executive committee members were involved in the study design, analysis and interpretation of the data, in the writing and review of the manuscript, and in the decision to submit the manuscript for publication.

## Summary

### Background

The long-term progression of coronary artery disease (CAD) as defined by the natural course of the disease years after a myocardial infarction (MI) is an important area of clinical research that has been poorly studied. The “long-Term risk, clinical management and healthcare Resource utilization of stable coronary artery disease in post myocardial infarction patients” (TIGRIS) study was designed to address this knowledge gap by evaluating patient management and clinical outcomes following MI in different regions worldwide.

### Methods

TIGRIS (ClinicalTrials.gov Identifier: NCT01866904) is a multi-center, observational, prospective, longitudinal study enrolling patients with history of MI 1 to 3 years previously and high-risk of developing atherothrombotic events in a general practice setting. Overall, 9,225 patients are being followed in 369 different centers worldwide, which will allow for the description of regional differences in patient characteristics, risk profiles, medical treatment patterns, clinical outcomes, and healthcare resource utilization. Patients will be followed for up to 3 years (minimum of 2 years).

### Discussion

We report the rationale, design, patient distribution and selected baseline characteristics of the TIGRIS study. This study will describe real-world management, quality of life, and healthcare resource utilization for patients with stable CAD at least 1-year post MI.

## 1. Introduction

Atherosclerotic plaque ulceration, erosion, or rupture, followed by platelet activation and thrombus formation is thought to constitute the main cause of cardiovascular (CV) events. Medical management of patients after an acute coronary syndrome (ACS) is based on multiple randomized clinical trials defining the acute, typically first year, treatment after the index event. While evidence-based management has reduced mortality significantly in recent years, patients surviving the first year after an ACS remain at high-risk for future CV events.<sup>1-4</sup> This risk is aggravated by distinct comorbidities, including hypertension, diabetes mellitus and chronic renal dysfunction as well as a history of recurrent myocardial infarction (MI) or documented history of angiographic evidence of multi-vessel coronary artery disease (CAD).<sup>5-7</sup> These comorbidities will also impact on medical management.

With better survival of the first year after an ACS, the prevalence of this high-risk population is growing worldwide, and rehospitalization remains frequent and unchanged over decades.<sup>8,9</sup> Therefore, it is important to establish an understanding of the demographics, treatments, and outcomes of these patients over time. The availability of the “long-Term risk, clinical management and healthcare Resource utilization of stable coronary artery disease patients in post myocardial infarction patients” (TIGRIS) registry will complement the current armament of generally country-specific registries of variable design, that render extrapolation of observations to other countries and regions difficult.<sup>10,11</sup> Furthermore, the limited information that is available suggests that management patterns and outcomes may vary for different nations. Direct comparisons of regional differences in post-MI



1  
2  
3 management and outcomes would be facilitated through the standardized  
4  
5 aggregation of this information across different countries.  
6  
7

8           The TIGRIS study was initiated to achieve this objective. The goal of TIGRIS is  
9  
10 to provide a standardized prospective and longitudinal description of patient  
11  
12 characteristics, events (per person years at 12 and 24 months), healthcare resource  
13  
14 utilization and current treatment patterns as seen in a relatively unselected patient  
15  
16 population post ACS. In this prospective observational study, patients from 25  
17  
18 different countries with a previous MI 1 to 3 years before enrollment in the registry  
19  
20 and at high-risk of developing future atherothrombotic events, will be followed for up  
21  
22 to 3 years (minimum of 2 years).  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 2. Methods

### 2.1 Overall study design

TIGRIS (clinicaltrials.gov NCT01866904) is ongoing with a follow-up period of up to 3 years. All patients undergo routine clinical assessments and receive the standard medical care, as determined by the treating physician. Patients will not receive any experimental intervention or treatment because of their participation in the study. The overall study design and patient flow chart is shown in Figure 1.

### 2.2 Study population

TIGRIS includes patients aged 50 years or older with a documented history of presumed spontaneous MI with their most recent MI having occurred 1 to 3 years prior to enrollment, and with at least 1 of the following risk factors:  $\geq 65$  years, diabetes treated with medication, documented history of a second MI  $> 1$  year prior to enrollment, multi-vessel CAD, and/or chronic non-end stage renal dysfunction (creatinine clearance calculated by Cockcroft Gault equation 15 mL/min to  $< 60$  mL/min). All patients provided written informed consent for participation. The inclusion and exclusion criteria are described in Table 1.

### 2.3 Aim and objectives

The TIGRIS study will evaluate prospectively over a follow-up period of up to 3 years (minimum of 2 years), the risk for recurrent CV events in this high-risk stable post MI population. The primary objective is to evaluate clinical events and healthcare resource utilization associated with hospitalization for these events (duration of hospitalizations, and procedures) over the follow-up period. Secondary objectives are

1  
2  
3 to describe the rate of individual ischemic events as described above, including CV-  
4 related death and death for unknown reasons and ischemic stroke, and to evaluate  
5 the incidence of bleeding events requiring medical attention. Other objectives are to  
6 describe associations between patient characteristics with quality of life and with the  
7 use (duration, adherence, discontinuation) of evidence-based therapies, association  
8 between oral antiplatelet therapy and clinical events (ischemic, death for any cause,  
9 and bleeding; including in high-risk subgroups such as the elderly, diabetic, renally  
10 impaired, or with recurrent MI), and to describe risk factor control in this high-risk  
11 population.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

#### 24 **2.4 Site selection and patient enrollment**

25  
26 In total, 334 sites (333 active with at least 1 patient recruited, and 1 site with no  
27 patients) have participated in the TIGRIS study in 25 countries worldwide. A National  
28 Principal Investigator (NPI) was identified for each participating country. In an attempt  
29 to obtain a representative sample at a country level, recruitment of sites and subjects  
30 was initially based on predefined selection of physicians (office-based primary care  
31 physicians and cardiologists as well as cardiologists based in hospitals with  
32 outpatient clinics) by NPIs; this was intended to provide a distribution of physicians  
33 across regions and locations (ie, urban, suburban, or rural areas). The aim was for  
34 each participating site to enroll at least 10 patients. A complete list of participating  
35 sites and principal investigators is provided in Appendix I (supplementary materials).  
36  
37 All patients will be followed up to 3 years in accordance with the overall patient flow  
38 chart shown in Figure 1.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 2.5 Study duration and phases

The planned duration of the study is from June 2013 (first patient in) until September 2017 (last subject last visit). Data collection is performed during the initial visit, and every 6 months such that every patient will have between 2 and 3 years of follow-up. These follow-ups are conducted either by a telephone call or personal visit (Figure 1). This provides information on these high-risk patients for a period from a minimum of 1 year to a maximum of 6 years since the index MI event.

## 2.6 Study variables

Variables obtained during the baseline visit were patient demographics including gender, age, race, place and type of residence, education level, and professional status. Sociodemographics including living arrangement status, income, and health insurance status were also collected. In addition, the prevalence of CV and bleeding risk factors, history of CAD and other CV disease as well as details of the medical history related to the index MI with a focus on antithrombotic medications has been assessed.

Variables from routine physical examination (heart rate, blood pressure [BP], weight, height, waist circumference) and from existing routine lab test (renal function tests, lipid profile, hemoglobin and glucose/glycated hemoglobin) if they were available and were performed within 3 months prior to the visit and up to 1 month after the visit (assuming no clinical events within this time window) were also captured in the initial visit.

Emphasis was paid to healthcare utilization related to CV or bleeding conditions during 6 months preceding enrollment.

1  
2  
3 Measures of health status as assessed by the EuroQol 5-Dimensions (EQ-5D)  
4 and EuroQol Visual Analog Scale (EQ-VAS) were collected at baseline. This  
5  
6  
7 measures self-reported health status in 5 dimensions (EQ-5D™; mobility, self-care,  
8  
9  
10 usual activities, pain or discomfort, anxiety or depression) with 3 levels of severity  
11  
12 (none, moderate, severe). For each patient, a single health state value, or utility, was  
13  
14 calculated (EQ-Index and EQ-VAS scores) and set on a scale ranging from 0 (which  
15  
16 corresponds to death) to 1 (EQ-Index) or from 0 to 100 (EQ-VAS; which corresponds  
17  
18 to a best imaginable state of health).  
19

20  
21 Information was also collected at baseline regarding clinics/outpatient center  
22  
23 characteristics.  
24

25  
26  
27 During the follow-up period, clinical outcomes (death, CV events, and bleeding  
28  
29 events), antithrombotic medications and other evidence-based medications, patient-  
30  
31 reported health status assessed by the EQ-5D are collected. Productivity loss such  
32  
33 as sick leave for the patient and the caregiver which is event-related are being  
34  
35 captured from a subset of around 10% of the study population from several countries  
36  
37 where this information was considered particularly relevant (Nordic Region and The  
38  
39 Netherlands). A complete list of variables captured in the study at baseline and  
40  
41 during follow-up, are provided in Appendix II (supplementary materials).  
42  
43  
44

## 45 46 **2.7 Collection of data**

47  
48 The data are collected using electronic case report forms (eCRFs). Initial data  
49  
50 collection was performed by the investigator. During the follow-up period, patients are  
51  
52 either contacted via telephone every 6 months or attend for a study visit from the site.  
53  
54 Follow-up phone calls are performed by either trained staff from the enrolling hospital  
55  
56

1  
2  
3 or from a designated call center, in accordance with a standard protocol to assist in  
4  
5 recording of treatments, events and medical visits.  
6  
7

8  
9 At each follow-up time point predefined clinical outcome events in the study as  
10 well as the variables related to associated healthcare utilization during hospitalization  
11 are collected directly from the treating physician/hospital through a standardized  
12 event confirmation eCRF and hospital module in the eCRF respectively in  
13 accordance with the following protocol. If, during interview, the patient or relative  
14 reports a predefined CV or bleeding-related hospitalization, the treating physician or  
15 hospital is contacted for confirmation of this event. Further information allowing  
16 determination of final diagnosis, primary cause of hospitalization, duration of hospital  
17 stay, procedures and interventions, and related healthcare resource utilization during  
18 hospital stay is collected from the treating physician or hospital directly through a  
19 standardized hospital module in the eCRF. If a death occurred, efforts are made to  
20 identify the cause of death (CV-related or non-CV) through the death certificate  
21 where available, or relatives, physicians, hospitals where it is not.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

## 38 **2.8 Statistical methods and sample size determination**

39  
40 This is a descriptive observational study without predefined hypothesis testing. The  
41 primary objective is to describe the incidence of CV events (time to first occurrence of  
42 any event from the composite CV endpoint of MI, unstable angina with urgent  
43 revascularization, stroke or death from any cause). The envisaged statistical methods  
44 included the description of the patients in accordance with their inclusion risk factors  
45 that define high-risk CAD:  $\geq 65$  years; treated diabetes; documented history of a  
46 second MI  $> 1$  year prior to enrollment; multi-vessel CAD; and/or chronic renal  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 dysfunction. Medication, and specifically the use of antithrombotic medication, over  
4  
5 the study period will be described in terms of use at specific time points during follow-  
6  
7 up, as well as the duration of antithrombotic medication and changes in regimen. EQ-  
8  
9 5D data collected during the study will be reported descriptively. Healthcare resource  
10  
11 utilization associated with events reported during the follow-up period will be  
12  
13 assessed.

14  
15  
16  
17 Events will be calculated both as risk (cumulative incidence) and rate using  
18  
19 person-time methods whereby follow-up either terminates at the first occurrence or is  
20  
21 censored at the last contact with the patient.  
22  
23

24  
25 No formal power calculation has been undertaken for this descriptive study.  
26  
27 Sample size was primarily driven by the country's needs based on payer  
28  
29 requirements from their markets. Initially a sample size of 10,170 patients was  
30  
31 estimated; due to delays in ethical approval in some countries, 9,225 patients were  
32  
33 ultimately recruited into the study.  
34  
35

## 36 37 **2.9 Ethics approval**

38  
39 The final protocol was approved by the relevant ethics committee from each country,  
40  
41 and the site ethics committee. The study is being performed in accordance with  
42  
43 ethical principles consistent with the Declaration of Helsinki revision, International  
44  
45 Conference on Harmonization Good Clinical Practice guideline, and the applicable  
46  
47 legislation on non-interventional studies.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 2.10 Funding and responsibilities

TIGRIS is sponsored by AstraZeneca and is non-interventional in nature, with no drugs being supplied or funded. The TIGRIS Executive Committee comprises 12 members (7 cardiologists, 1 clinical pharmacologist, 1 health economist and 1 statistician, and 2 representatives from AstraZeneca). The executive committee with support from AstraZeneca is responsible for the design and conduct of this study, and all study analyses.

## 2.11 Participating regions

The participating regions were: Asia-Pacific, with 5 countries: Australia, China, India, Japan, and South Korea (n = 2,850 patients, 31%); Europe with 13 countries: Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Portugal, Romania, Spain, Turkey, and the UK (n = 4,240 patients, 46%); North America: Canada and USA (n = 1,024 patients, 11%); and South America, with 5 countries: Argentina, Brazil, Colombia, Mexico, and Venezuela (n = 1,111 patients, 12%) (Table 2 and Figure 2).

## 2.12 Patient characteristics

Characteristics of patients in TIGRIS are shown in Table 2. Patients in Asia-Pacific and South America were younger, hence the risk factor age over 65 years was less frequently met as an inclusion criterion; there was a higher percentage of patients with treated diabetes mellitus in these 2 regions compared to patients from Europe or North America. On the other hand, the percentage of patients with a second prior MI (before the index MI) was higher in Europe and North America, while multi-vessel



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

CAD was seen more frequently in patients from North America and Asia-Pacific. The rates of chronic renal dysfunction were similarly distributed worldwide.

For Peer Review

### 3. Discussion

This report describes the rationale and design of the TIGRIS study, which is unique in being a study of unselected patients that reflects the heterogeneity of patients who have stable CAD but are at high-risk. Specifically, TIGRIS will address regional differences in patient characteristics, clinical outcomes, medical treatment patterns, and healthcare resource utilization of patients with high-risk of future CV events 1 to 3 years post MI.

The risk of future CV events in patients with a history of MI is increased by comorbidities like diabetes mellitus, chronic kidney disease as well as the age and the complexity of CAD. While many randomized clinical trials have addressed this risk with emphasis on the first 12 months after an MI, little is known about the risk of subsequent ischemic events beyond this time in a “real-world” population. The improved survival post MI and the aging population are creating an emerging population for whom there is a problematic knowledge gap; specifically, there is a growing number of patients with a remote history of MI for whom there is little evidence to guide appropriate treatment.

Recently, Jernberg and colleagues published outcome data from a large Swedish national registry including 108,315 patients after MI with long-term follow-up.<sup>12</sup> Overall, 10% of the patients died during the hospital stay and within 1 week after hospital discharge, and an additional 12.3% over the following year. The cumulative rate of the CV composite outcome, including recurrent MI and stroke and CV death, was 18.3% in the first year after a MI. The CV risk remained high with 9.0% in the next 12 months and 20.0% in the following 36 months. Similarly,

1  
2  
3 Rapsomaniki and colleagues investigated patients aged 65 years and older from 1  
4 year following a MI in the 4-nation APOLLO study. The adjusted risk of mortality over  
5 the subsequent 3 years ranged from 12.8% to 19.5%; the corresponding risks of  
6 hospitalized bleeding events ranged from 2.7% to 4.9%.<sup>13</sup> These data, derived from  
7 datasets from France, Sweden, the United States and the United Kingdom, were  
8 generated for a variety of purposes using different collection and validation  
9 methodologies, hence it is difficult to ascertain whether the variation in event rates  
10 between countries reflected real differences, or variations in methodology.  
11  
12  
13  
14  
15  
16  
17  
18  
19

20  
21 In 2 recently reported acute dual antiplatelet therapy randomized clinical trials,  
22 mortality risk (Kaplan-Meier) in the 12 months following randomization were generally  
23 low eg, for PLATO (4.5% ticagrelor; 5.9% clopidogrel)<sup>14</sup> and TRITON (3% prasugrel;  
24 3.2%; clopidogrel).<sup>15</sup> PEGASUS investigated the long-term addition of ticagrelor to  
25 aspirin initiating treatment 1 to 3 years after a MI.<sup>16</sup> The 3-year Kaplan-Meier  
26 mortality risk was 5.2% in the aspirin arm, substantially lower than that observed in  
27 the APOLLO program. Therefore, it is clear, compared to more selected and  
28 generally younger patients within randomized clinical trials, the unselected population  
29 has a substantially higher risk.<sup>17</sup> This emphasizes the need for 'real-world' data  
30 collected using standardized rigorous consistent methodology to access outcomes  
31 during the years following a MI.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46  
47 In addition to the provision of representative, general practice evidence, a  
48 major strength of TIGRIS is the focus on different countries. Notably, 30% of study  
49 patients derive from Asia-Pacific and 12% from South America, areas where the  
50 availability of such information is relatively limited. This study has already shown that  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 post-MI patients from Asia-Pacific and South America are younger and have a higher  
4  
5 incidence of diabetes mellitus compared to patients from Europe or North America.  
6

7  
8 Given these baseline differences in populations, TIGRIS will provide unique  
9  
10 information on comparative outcomes and healthcare resource utilization in the years  
11  
12 after a MI. Interpretation of these outcomes will be greatly aided though the recording  
13  
14 of medical management patterns in different international settings and their  
15  
16 association with clinical outcomes.  
17

18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

#### 4. Conclusion

In conclusion, TIGRIS is a unique study that documents demographics, comorbidities, treatment patterns and outcome data in unselected stable CAD patients with previous MI in general practice settings. Data are being collected internationally in a rigorous, standardized and consistent fashion providing a relevant picture of both the burden of recurrent events and variability in management and outcomes in this poorly studied patient population.

For Peer Review

## Acknowledgements

The authors would like to thank the patients, their families and all investigators involved in this study. Assistance with project management, site management, data management, and regulatory affairs was provided by Worldwide Clinical Trials Evidence Group, Nottingham, England, United Kingdom. Medical writing support was provided by Carl V Felton PhD of Prime, Knutsford, UK, in accordance with Good Publication Practice guidelines ([Link](#)) and funded by AstraZeneca. AstraZeneca was involved in the study design, collection, analysis and interpretation of data, as well as data checking of information provided in the manuscript. However, ultimate responsibility for opinions, conclusions, and data interpretation lies with the authors.

**Authorship contributions**

Stefan Blankenberg	Study design, data analysis and interpretation, drafting and revision of the manuscript
Dirk Westermann	Data analysis and interpretation, drafting and revision of the manuscript
Shaun G. Goodman	Study design, data analysis and interpretation, and revision of the manuscript
Jose Carlos Nicolau	Study design, data analysis and interpretation, manuscript revision
Gema Requena	Study design, data analysis and interpretation, manuscript revision
Andrew Maguire	Study design, data analysis and interpretation, manuscript revision
Ji Yan Chen	Study design, data analysis and interpretation, manuscript revision
Christopher B Granger	Study design, data analysis and interpretation, manuscript revision
Richard Grieve	Study design, data analysis and interpretation, manuscript revision
Stuart J. Pocock	Study design, data analysis and interpretation, manuscript revision
Tabassome Simon	Study design, data analysis and interpretation, manuscript revision
Satoshi Yasuda	Study design, data analysis and interpretation, manuscript revision
Ana Maria Vega	Study design, data analysis and interpretation, manuscript revision
David Brieger	Study design, data analysis and interpretation, manuscript revision

## References

1. Simms AD, Weston CF, West RM, et al. Mortality and missed opportunities along the pathway of care for ST-elevation myocardial infarction: A national cohort study. *Eur Heart J Acute Cardiovasc Care*. 2015;4:241-253.
2. Puymirat E, Schiele F, Steg PG, et al. Determinants of improved one-year survival in non-ST-segment elevation myocardial infarction patients: Insights from the French FAST-MI program over 15 years. *Int J Cardiol*. 2014;177:281-286.
3. Puymirat E, Simon T, Steg PG, et al. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. *JAMA*. 2012;308:998-1006.
4. Fox KA, Carruthers KF, Dunbar DR, et al. Underestimated and under-recognized: The late consequences of acute coronary syndrome (GRACE UK-Belgian Study). *Eur Heart J*. 2010;31:2755-2764.
5. Nauta ST, Deckers JW, van der Boon RM, et al. Risk factors for coronary heart disease and survival after myocardial infarction. *Eur J Prev Cardiol*. 2014;21:576-583.
6. Min JK, Dunning A, Lin FY, et al. Age- and sex-related differences in all-cause mortality risk based on coronary computed tomography angiography findings results from the International Multicenter CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry) of 23,854 patients without known coronary artery disease. *J Am Coll Cardiol*. 2011;58:849-860.



- 1  
2  
3 7. Zengin E, Bickel C, Schnabel RB, et al. Risk factors of coronary artery disease  
4  
5 in secondary prevention--results from the AtheroGene--study. *PLoS One*.  
6  
7 2015;10:e0131434.  
8
- 9  
10 8. Krumholz HM, Nuti SV, Downing NS, et al. Mortality, hospitalizations, and  
11  
12 expenditures for the Medicare population aged 65 years or older, 1999-2013. *JAMA*.  
13  
14 2015;314:355-365.  
15
- 16  
17 9. Chen HY, Tisminetzky M, Yarzebski J, et al. Decade-long trends in the  
18  
19 frequency of 90-day rehospitalizations after hospital discharge for acute myocardial  
20  
21 infarction. *Am J Cardiol*. 2016;117:743-748.  
22  
23
- 24  
25 10. Chan MY, Du X, Eccleston D, et al. Acute coronary syndrome in the Asia-  
26  
27 Pacific region. *Int J Cardiol*. 2016;202:861-869.  
28  
29
- 30  
31 11. Gitt AK, Bueno H, Danchin N, et al. The role of cardiac registries in evidence-  
32  
33 based medicine. *Eur Heart J*. 2010;31:525-529.  
34  
35
- 36  
37 12. Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-  
38  
39 myocardial infarction patients: Nationwide real world data demonstrate the  
40  
41 importance of a long-term perspective. *Eur Heart J*. 2015;36:1163-1170.  
42  
43
- 44  
45 13. Rapsomaniki E, Thuresson M, Yang E, et al. Using big data from health  
46  
47 records from four countries to evaluate chronic disease outcomes: A study in 114 364  
48  
49 survivors of myocardial infarction. *Eur Heart J Qual Care Clin Outcomes*. 2016;2:172-  
50  
51 183.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 14. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in  
4 patients with acute coronary syndromes. *N Engl J Med*. 2009;361:1045-1057.  
5  
6  
7  
8 15. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in  
9 patients with acute coronary syndromes. *N Engl J Med*. 2007;357:2001-2015.  
10  
11  
12  
13 16. Bonaca MP, Braunwald E, Sabatine MS. Long-term use of ticagrelor in  
14 patients with prior myocardial infarction. *N Engl J Med*. 2015;373:1274-1275.  
15  
16  
17  
18  
19 17. Chung SC, Gedeberg R, Nicholas O, et al. Acute myocardial infarction: A  
20 comparison of short-term survival in national outcome registries in Sweden and the  
21 UK. *Lancet*. 2014;383:1305-1312.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Figure legends

Figure 1: Study design

MI, myocardial infarction; QoL, quality of life

Figure 2: Patient enrollment in “long-Term risk, clinical management and healthcare

Resource utilization of stable coronary artery disease patients in post myocardial

infarction patients” (TIGRIS) by country and region

For Peer Review

**Table 1: Inclusion and exclusion criteria**

Inclusion criteria	Exclusion criteria
<ul style="list-style-type: none"> <li>• Age <math>\geq</math> 65 years</li> <li>• Diabetes mellitus requiring medication</li> <li>• Documented history of a second prior presumed spontaneous MI (&gt;1 year ago)</li> <li>• Documented history of angiographic evidence of multi-vessel coronary artery disease</li> <li>• Chronic, non-end stage renal dysfunction (15 mL/min <math>\leq</math> creatinine clearance calculated by Cockcroft Gault equation &lt;60 mL/min)</li> </ul>	<ul style="list-style-type: none"> <li>• Presence of any condition or circumstance which in the opinion of the investigator could significantly limit the complete follow-up of the patient (eg, tourist, non-native speaker or does not understand the local language where interpreter services are not reliably available, psychiatric disturbances, alcohol or drug abuse)</li> <li>• Presence of serious/severe co-morbidities in the opinion of the investigator which may limit life expectancy (&lt;1 year)</li> <li>• Current participation in a blinded randomized clinical trial</li> <li>• Patients receiving treatment with ticagrelor beyond 12 months, or off label use of ticagrelor</li> </ul>

MI, myocardial infarction

**Table 2: Patient characteristics**

Patients, n (%)	All	Asia-Pacific & Australia	Europe	North America	South America	<i>P</i>
Patients	9225 (100)	2850 (30.9)	4240 (46.0)	1024 (11.1)	1111 (12.0)	
Inclusion risk factors						
Age ≥ 65 years	5766 (62.5)	1652 (58.0)	2814 (66.4)	666 (65.0)	634 (57.1)	<0.001
Diabetes requiring medication	2805 (30.4)	999 (35.1)	1118 (26.4)	307 (30.0)	381 (34.3)	<0.001
Second prior MI	943 (10.2)	210 (7.4)	491 (11.6)	131 (12.8)	111 (10.0)	<0.001
Multi-vessel CAD	6052 (65.6)	1921 (67.4)	2714 (64.0)	715 (69.8)	702 (63.2)	<0.001
Chronic renal dysfunction (CrCl 15–60 mL/min)	707 (7.7)	212 (7.4)	327 (7.7)	78 (7.6)	90 (8.1)	0.898

CAD, coronary artery disease; CrCl, creatinine clearance; MI, myocardial infarction

*P*-values estimated using Chi square test




Figure 1: Study design

118x86mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2: Patient enrollment in “long-Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease patients in post myocardial infarction patients” (TIGRIS) by country and region

242x138mm (300 x 300 DPI)

## Supplementary Materials

### APPENDIX I: TIGRIS National principal investigators (NPIs) and site study investigators

Site name	Investigator	Sub-investigator(s) and coordinator(s)
<b>Asia</b>		
<b>China</b>		
<i>NPI:</i> G Junbo		
Zhongda Hospital affiliated to Southeast University	M Genshan	Z Hong; Z Kongbo
The 2 <sup>nd</sup> Hospital affiliated to Guangzhou Medical University	X Longgen	C Luo
Jinan Central Hospital affiliated to Shandong University	S Guohai	M Wei; W Fang; L Zhenhua
Guangdong General Hospital	C Jiyan	F Yingqing; C Anping
Zhongshan Hospital affiliated to Fu Dan University	G Junbo	Y Ming; X Lei
Shanxi CDV hospital	L Bao	A Jian; S Jing
Tianjin Union Medicine Center	Y Zhuhua	J Wang
1 <sup>st</sup> Hospital of Liao Ning Medical College	T Guizhou	M Liu
Fuwai CV Hospital	Q Shubin	S Chunli; L Xiaoliang; Liu Rong; Z Jun; L Jia
Beijing University 1 <sup>st</sup> Hospital	H Yong	Z Bo
The 1 <sup>st</sup> Hospital affiliated to Chongqing Medical University	L Han	H Wei; C Jing
Wuxi 2 <sup>nd</sup> People's Hospital	J Yan	
The 1 <sup>st</sup> Hospital of Jilin University	Z Yang	L Quan; W Yonggang
1 <sup>st</sup> Affiliated Hospital of Xi'an Jiaotong Univ, College	W Yanni	R Jie



Med		
The 1 <sup>st</sup> Hospital affiliated to Lanzhou University	Z Zheng	Z Cunrui
Tanjin Thoracic Hospital	C Hongliang	Z Yingyi
Kunming General Hospital of Chengdu Military Region	Y Lixia	F Jun
Wuxi People's Hospital	Y Zhenyu	B Xiaoping; Y Fang; Z Xiaoxi
The Affiliated Hospital of JiangSu University	Y Jinchuan	L Peijing; D Shu; W Jun
<b>India</b>		
<i>NPI</i> : K Upendra		
Meenakshi Mission Hospital & Research Centre, Madurai	R Sivakumar	J Balan
Sir Ganga Ram Hospital	JP Sawhney	R Gehlot; MK Sharma
Escorts Heart Institute, New Delhi	U Kaul	M Kent
G. B. Pant Hospital	V Mehta	S Dalal
Heart First Cardiac & Vascular Centre	A Abhyankar	A Mistry
Fortis, Jaipur	R Gupta	B Mishra; S Chaturvedi; P Saxena; MK Sharma
PRS Hospital, Trivandrum	T Nair	TC Aneesh
West Fort Hitech Hospital	PP Mohanan	D Davies
B. M. Birla Heart Research Center	D Kahali	S Chatterjee
Fortis Hospital, Mohali	HK Bali	H Chauhan
Fortis Hospital, Noida	P Arora	S Singh
Ruby Hospital, Pune	MS Hirematth	R Pawar
Madras Medical Mission	A Mullasari	R Bhavani
Apollo Hospital	PC Rath	Adepu Aruna; Byomkesh Dikshit
<b>Japan</b>		
<i>NPI</i> : S Yasuda		

Iwate Medical University	Y Morino	T Ito; M Ishida; T Mifune; Y Ishikawa; S Nakajima; M Nagai; T Fusazaki; T Kimura; Y Shimoda; R Sakamoto; Y Nakajima; K Komuro; Y Okuyama
St Luke's International Hospital	Y Nishi H Niinuma	H Mitsuhashi; K Masuda; A Mizuno; T Asano; I Komatsu; M Kikuchi; S Kimijima
Saiseikai Kumamoto Hospital	K Nakao	M Otaguro; K Nakano
Kimitsu Chuo Hospital	T Himi	M Yamamoto; H Fujimaki; Y Matsudo; T Sekine; K Hou; N Tonoike; S Tanaka; YHB Ge; S Tokimasa; A Fujino; S Hashidume
Kumamoto University Hospital	S Hokimoto	H Ogawa; Kenichi Tsujita; H Soejima; E Yamamoto; S Tayama; T Tanaka; S Kojima; Y Arima; M Yamamuro; K Sakamoto; Y Izumiya; S Takashio; T Akasaka; Y Kimura; H Kurokawa; K Yamanaga; N Komuro; T Miyazaki; K Nishiyama; Y Kawanami
Fujita Health University	Y Ozaki	E Watanbe; M Sarai; Y Kato; S Motoyama; H Naruse; Y Sobue; M Okumura; K Shiino; M Ohta; M Yamamoto; H Ito; Y Takakuwa; T Ichikawa; R Okuyama; M Ishikawa; M Koshikawa; Y Nagahara; M Miyagi; M Iwase; M Otsuki; N Hoshino; Y Hashimoto; T Muramatsu; S Matsui; S Ishikawa
Sapporo Medical University Hospital	T Miura	A Hashimoto; T Miki; H Yoshida; N Kokubu
Hirakata Kohsai Hospital	S Kitaguchi	M Ozaki; R Yamauchi; Y Haruna; H Takenaka; K Takenaka; T Yamamoto; Y Kurozumi; N Takemoto
Fukuoka University Hospital	K Saku	A Kawamura; H Nishikawa; A Iwata; K Fujimi; E Yahiro; M Sugihara; A Ike; K Urabe
Kitasato University Hospital	J Ako	T Tojo; T Shimohama; H Fukaya; T Naruke; H Shinagawa; J Kishihara; T Yanagisawa; Ouchi; K Yamamura
Nippon Medical School Hospital	W Shimizu	K Asai; H Takano; G Takagi; K Kato; M Yoshikawa; K Murai; S Nakamura; Y Tsukada; T Yamamoto; K Akutsu; Y Hosokawa; K Inui; E Nakamura; K Kawakami
Chikamori Hospital	K Kawai	R Imai; S Kubokawa; S Seki; S Yamamoto; Y Nakaoka; H Hosoda; T Matsui
Chiba University Hospital	Y Kobayashi	K Sugimoto; Y Aoki; K Ishikawa; M Takahara; T Nakayama
Fukui CardioVascular Center	S Mizuno	K Osato; I Moriuchi; T Murakami; K Misawa; H Kokado; M Saga; Ma

		Tsuchida; Y Takasawa; J Yamaguchi; M Suzuki; N Maekawa; S Yoneda
Ehime Prefectural Central Hospital	Y Kazatani	H Okayama; T Yamada; G Hiasa; Y Kawada; M Kinoshita; T Shigematsu; H Nakagawa; T Ozaki; S Hosokawa; M Matsubara; K Fukuchi
Ishikawa Prefecrual Central Hospital	H Kanaya K Miwa	T Matsubara; T Yasuda; M Inoue; Y Tamura; M Hashimoto; S Niwa; K Hakko
Tohoku University Hospital	H Shimokawa	J Takahashi; Y Matsumoto; K Ito; K Hao; R Tsuburaya; E Ishida
Yokohama City University Medical Center	N Maejima	K Kimura; T Ebina; K Hibi; K Konishi; N Iwahashi; T Matsuzawa; H Akiyama; Y Kimura; Y Minamimoto; K Matsushita; S Kataoka; S Ichikawa; S Kuji; K Takahashi; C Kawashima; K Hashiba; H Nakahashi; M Kosuge; M Ninomiya
Osaka City University Hospital	Y Minoru	M Yoshiyama; S Ehara; T Hasegawa; K Shimada
Gunma Prefectural Cardiovascular Center	R Kawaguchi	S Ooshima; H Kan; Y Miyaishi; M Maruhashi
Seiyu Memorial Hospital	Y Tomoguchi	S Fujiwara; Y Ueno; M Gohda; K Takei; Y Shimomoto
Shizuoka Hospital	T Onodera	R Nawada; K Murata; R Takeuchi; Y Watanabe; T Yoshizaki; S Kageyama; N Hosoya; T Takagi; S Yamashita; G Matsukura; A Fujinami
Tokushima Red Cross Hospital	S Hosokawa	Y Hiasa; R Ohtani; K Kishi; T Takahashi; K Yuba; H Miyajima; R Ogura; Y Tobbeto; T Yasuoka; Y Ooga; H Kiyobe; Y Shima
National Cerebral and Cardiovascular Center	M Ishihara; T Noguchi	S Yasuda; M Fujino; M Nakanishi; T Arakawa; R Kumasaka; T Kanaya; S Honda; T Nagai; Y Goto; Y Asaumi; K Nakao; M Kawakami; R Yamada; A Matsuyama; Y Kawakami; T Nishimura
Juntendo University Shizuoka Hospital	S Suwa	N Kubota; S Tsuboi; T Shimizu; H Wada; H Endo; Y Kato; M Sesoko; M Kunimoto; S Ouchi; J Shitara; K Shiba
Oji General Hospital	T Matsumoto	J Ohata; D Yoshida; N Kato; H Hotta; T Ito; S Tanaka; H Narikawa
Hyogo Prefectural Amagasaki General Medical Center	T Miyamoto	Y Takatsu; Y Sato; R Taniguchi; K Yoshitani; R Fukuhara; S Saga; T Kobayashi; H Shinomiya; S Imura; H Inazumi; T Kuragaichi; M Shiba; H Nakayama; C Uwajima; A Negimoto
Tenri Yorozu Hospital	S Enomoto;	S Enomoto; K Kaitani; C Izumi; T Tamura; H Kondo; N Onishi; M

	Y Nakagawa	Miyake; Y Tamaki; K Takahashi; N Kuroda
Kusatsu General Hospital	A Wada	M Fujii; T Matsumoto; K Mori; A Taniguchi; S Kimura; Y Fujito
Tokai University Hospital	Y Ikari	F Yoshimachi; N Ogata; N Shinozaki; N Masuda; G Nakazawa; T Murakami; T Nakano; M Sato; S Torii; H Nagamatsu; T Suzuki; H Shimizu; T Suzuki; S Minakawa; H Horinouchi
Kurume University	T Ueno	S Yokoyama; T Nakayoshi; N Itaya; M Sasaki; H Chibana; Y Aoki; K Sasaki; Y Sugi; M Otsuka; E Ogura
Hiroshima City Hospital	K Nishioka	Y Nakama; T Oka; K Dai; K Ooi
<b>South Korea</b>		
<i>NPI:</i> Y-J Kim		
Wonju Christian Hospital	J Yoon	SH Han
Pusan National University Hospital	K Soo Cha	HC Lee; J-H Oh; J-H Choi; HW Lee; J Lee; J Hong; SH Ji; WJ Kim
Kosin University Gospel Hospital	T-J Cha	IK Noh
Chonbuk National University Hospital	J-K Chae	EJ Cho; JY Hong; SM Lee
Keimyung University Dongsan Hospital	C-W Nam	M Y Shin; M H Choi
Chung-Ang University Hospital	S W Kim	KH Kim; M Choi
Inje University Haeundae Paik Hospital	D Kim	KN Park
Chungbuk National University Hospital	M-C Cho; SM Kim	CS Lee; EK Kim
Chonnam National University Hospital	M-H Jeong	KH Park; DS Sim; YJ Hong; A Choi; C Kim
Gyeongsang National University Hospital	Y-H Jeong; JS Koh	CH Kwak; J-Y Hwang; JR Park; ES Kim
Yeungnam University Hospital	Y-J Kim	D Shin; JS Park; SH Lee; U Kim; JW Son; KH Yim; YM Ha; HS Lee; JM Kim
Chungnam National University Hospital	S W Choi	JH Lee; NM Jeon
<b>Australia</b>		
<i>NPI:</i> D Brieger		

Concord Hospital	D Brieger	K Xu
John Hunter Hospital	N Collins	A Gordon; E Hicks
St George Hospital	M Sader	P Shrestha; K Dobinson; J Brimley; D Vrachas; E Watson
Royal Brisbane and Women's Hospital	C Hammett	L Carr; C Booth; S Hayman; A Brazzale; C Cosgrove; A Lin; G Goodman; L Palethorpe; L Hindom; L Lilwall
Wollongong Hospital	A Lee	P Hedge; D Devenney; T Fetahovic; S Mackay; J Gibbs
Royal North Shore Hospital	G Nelson	M Ward; E Reid; A Loxten
Princess Alexandra Hospital	P Garrahy	C Hall; C Sieg
Sir Charles Gairdner Hospital	P Thompson	C-Di Camillo; H Anderson; L Ferguson; S Zafer; K Mohammadi; S Nagel
Gold Coast Hospital	R Jayasinghe	L Howes; S Quinlan; T Brumbly
Royal Melbourne Hospital	D Eccleston	K Phan; J Ward
Northern Hospital	W van Gaal	I Subiatko; N Rudd; M Park
Fremantle Hospital	A Whelan	R Kamne; S Atique; T Nunn; A Rehmani; D Greenwell; G Tulloch; N Forrest
Liverpool Hospital	J French	E Plotz; A Croucher
Coffs Harbour Base Hospital	J Waites	V Joseph; P Keays; L Gill
Epworth Hospital	R Dick	C Savage; B Slait
Nambour General Hospital	A Willson	R Poulter; M Johnson; P Larsen; S Wadham; M Fellner; L Webber; K Greaves
<b>Europe</b>		
<b>Belgium</b>		
<i>NPI</i> : M Vrolix		
ZOL Genk	M Vrolix	W Helsen; N Peters; C Swijsen
OLV Aalst	E Barbato; C Van Mieghem	E Lievens; H Batjoens

1			
2			
3			
4			
5	AstraZeneca (AZ) St Augustinus Veurne	M Detollenaere	L De Bruyne; M Everaert
6	AZ Klina	F Cools	N Simons; V Thyssen
7	Imelda Bonheiden	B Vankelecom	Y Daelemans; C Vissers; R Janssens
8	Maria Ziekenhuis Overpelt	D Faes	A Van Dorpe
9	UZ Gent	S Gevaert	P Vervaet
10	AZ Groeninge - Campus LS	P Dejaegher	M DeConinck
11	<b>Denmark</b>		
12	<i>NPI:</i> H Nielsen		
13	Hjerteklinikken Plan 5 Regionshospitalet Randers	H Rickers	B W Friis; M Morsing
14	Gentofte Hospital Hellerup	J S Jensen	J Laage-Petersen; LH Simonsen
15	Rigshospitalet Hjertecentret, København	L Holmvang	A Karlsdottir; L Klovgard; SB Nielsen; M Tarras-Wahberg
16	Bispebjerg Hospital	H Nielsen	E Stokholm; B Hauggaard; D Petersen
17	Ålborg Sygehus	L H Rasmussen	A Gammelmark; BG Sorensen; F Hellum; B Mortensen
18	Amager Hospital, København S.	J Brønnum-Schou	JB LLægelig; H Hempel; P Hadsund
19	Haderslev Sygehus Kardiologisk sektion	E V Friis	C Markussen; I Christensen
20	<b>Finland</b>		
21	<i>NPI:</i> I Tierala		
22	Turku University Hospital	J Airaksinen	K Lahtonen; T Vasankari
23	Tampere University Hospital	S Vikman	V Rasanen; H Nappile; H Schemakka
24	Keski-Suomen keskussairaala	J Niva	
25	<b>France</b>		
26	<i>NPI:</i> T Cuisset		
27	Hôpital Pasteur	E Ferrari	L Marthoud; M Douillet
28	Centre Hospitalier Louis Pasteur	G Range	C Laure
29			
30			
31			
32			
33			
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			

Centre Hospitalier de Versailles	J L Georges	J B Azowa
CH St Joseph St Luc - LYON	O Dubreuil	S Rio
Hôpital de bligny	A Ohanessian	
CHU de la Timone, Marseille	T Cuisset	
Centre Hospitalier Sud Francilien, Service de cardiologie	P Goube	P Brito
<b>Germany</b>		
<i>NPI:</i> S Blankenberg		
Klinikum Leverkusen gGmbH	P Schwimmbeck	I Wenzel
Robert-Bosch-Krankenhaus	T Schäufele	I Wenzelburger
Medizinische Klinik II am UKSH Campus Luebeck	A Joost	A Constantz; C Lüttecke; M Werner
St. Josefs Hospital	S Lüders	U Venneklaas; I Medizin
Univ.-Klinikum	E Giannitsis	H Deigentasch; S Stegmaier
Klinikum Coburg gGmbH	J Brachmann	A Hoehn; U Göbel
Klinikum Stadt Ludwigshafen Herzzentrum	U Zeymer	H Tolksdorf; S Baumann; N Veth-Leonhardt; P Riedmaier
Kliniken Maria Hilf GmbH	J vom Dahl	U Gareis; B Krug-Hoeren
Carl-von-Basedow-Klinikum Merseburg	R Prondzinsky	D Brosseit; S Koegel
Elisabeth-Krankenhaus	O Bruder	E Blank; V Reuter; M Steffen
Universitäres Herzzentrum Hamburg	D Westermann	M Redlefsen; E P Tigges; M Hermes; I de Boer; M Redlefsen; M Karakas
Universitätsmedizin der Johannes Gutenberg-Universität Mainz	T Gori	I Walther; K Schulz
Kardiologie am Tibarg	F Stahl	J Schiller
University Heart Center Köln (Cologne)	V Rudolph	I Berg
Sana Kliniken Lübeck	J Weil	M Miodek; T Köllner
Heidekreis-Klinikum GmbH	T Wittlinger	A-K Cohrs; V Wiechern

Vivantes Humboldt-Klinikum	S Behrens	M Gregor; R Sartipi
CardioMed an der Alster	B Subin	N Zahn
Charite, Campus Benjamin Franklin	M Gross; SM Leistner	S Kuehn
Kardiologischen Gemeinschaftspraxis am Park Sanssouci Potsdam (St. Josefskrankenhaus)	R Gaub	V Gaertner
Krankenhaus Dresden-Friedrichstadt II. Medizinische Klinik, Dresden	S Schellong	R Frommhold; B Voigts; L Pomper; J Gehre; M Hahn; M Langer; R Oelsner; T Wolf
Cardiologicum Hamburg Praxis Wandsbek	E Schmidt	A Rexa; C Züge; V Bogoevska
University of Ulm Medical Center	S Markovic	O Smirnova; A Maass; K Kraus; M Holl; U Schneeu
Katholisches Krankenhaus St. Johann Nepomuk Medizinische Klinik II	H Ebelt	J Anacker
Kardiologische Praxis	J Bott	M Erdas; J Bott
Klinikum Frankfurt Höchst GmbH	C Kadel	G Rahn; N Zulauf
Medizinisches Beratungs- und Therapie-Zentrum Chemnitz GmbH	K Kleinertz	E von der Planitz; F Froehlich-Grimm; S Geserick
Städtisches Klinikum München GmbH	H Mudra	P Setzer; J Fiedler; M Segerer; A Stote
Vivantes Klinikum Neukölln	H Darius	A Maselli; G Biller; S Bodogh; S Gaulke
Universitätsklinikum Erlangen	S Achenbach	C Uecker; S Fechner
Synexus Frankfurt Research Centre, Frankfurt	C Contzen	N Freibott
Synexus Berlin Research Centre, Berlin	J Stößel	F Bauch; T Trachte; AM Peukert
Synexus Leipzig Research Centre	K Kreutzmann; O Maus	H Knopf; I Schiefer; N Zimmer; T Kusly
Synexus Bochum Research Centre	A Rinke	A Rauscher; S Laube; P Doelken
Bundeswehrzentral Krankenhaus Klinik für Innere Medizin	C Bickel	B Jürgens; M Halfter
<b>Italy</b>		



<i>NPI: C Cavallini</i>		
Ospedale Santa Maria della Misericordia	C Cavallini	E Grikstaite
Presidio Ospedaliero Ca' Foncello, Treviso	Z Olivari	P Pantano
Ospedale del Delta, Lagosanto	GF Percoco; R Mazzucco	
Centro Cardiologico Monzino	G Marenzi	M De Metrio
Ospedale Pediatrico Apuano G. Pasquinucci	S Berti	KJ Tyack; E Koni
A.O.U. Federico II	PP Filardi	T Losco; S Conte; L Casaretti
Ospedale Misericordia e Dolce di Prato	F Pestelli	-
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone di Palermo	S Novo	C Vicari; C Paleologo
Cardiologia del Policlinico S. Orsola di Bologna	A Branzi; C Rapezzi	G Melandri; G Norscini
Azienda Ospedaliera per l'Emergenza "Cannizzaro"	A Fiscella; C Condorelli	M Pardini
Ospedale Unico della Versilia	G Casolo	M Pardini; L Robiglio; F Vivaldi
ASL Sassari Ospedale Civile S.S. Annunziata	P F Terrosu	C Poddighe; C Denurra; G Sanna; A Canu; E Mura
Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli	C Mauro	D D'Andrea; A Sasso; F Furbatto
<b>The Netherlands</b>		
<i>NPI: AFM Kuijper</i>		
BovenIJziekenhuis	M van de Wetering	L Klijn; SJ Groeneveld
Rijnstate Ziekenhuis	FF Willems	E Maasen; J Marx; A Dekker; E Verhaah; P Verhoeven
Tergooiziekenhuizen, loc. Blaricum	G Hoedemaker	M van der Zeijst
IJsselland Ziekenhuis	B J Berg van den	I Hendriks

Reinier de Graaf Gasthuis	E Ronner	A Wissenburg; L van Setten van der Meer; L van der Hout; A Dijkshoorn
HagaZiekenhuis, loc. Leyenburg	M JW Götte	M Hugo; E Karijodikoro; C de Jonge; H de Lange-van Bruggen
Slingeland Ziekenhuis	JCM Hal van; DAAM Schellings	
Ziekenhuis Gelderse Vallei	F den Hartog	D van Wijk; M Singerling
Martini Ziekenhuis	GL Bartels	M Hendriks - van Woerden; B van der Roest; Z Aukema-Wouda
Kennemer Gasthuis - locatie EG	JF Küpper	J Vooges; C Kalkman
Röpcke Zweers Ziekenhuis	HP Beijerbacht	M Beijering; B Baarslag
Atrium Medisch Centrum	T Lenderink	I Kremer
Spaarne Ziekenhuis	AFM Kuijper	M Schiks; E Bayraktar
Orbis Medisch Centrum	MERM van Daele	O Douven; M Bouwens
Gelre Ziekenhuizen, loc. Zupthen	NYY Al-Windy	T Tiemes; M van Nistelrooy
Ziekenhuis Bethesda	SHK The	F Geerlings; J Krikken
<b>Norway</b>		
<i>NPI:</i> F Kontny		
Stavanger Universitetssjukehus Helse Stavanger	D Nilsen	S Moen; T Brugger-Andersen; V Ponitz
Diakonhjemmet Sykehus	EH Oie	H Muriq; RU Quazi
Sykehuset Ostfold	RAM deBoer	
<b>Portugal</b>		
<i>NPI:</i> C Gavina		
Unidade Local de Saúde de Matosinhos	C Gavina	C Ponte; M Centeno; H Maia; I Goncalves; R Barrades; J Tavares
Unidade Saúde Familiar Santo André de Canidelo	F Ferreira	L Alves
Unidade Saúde Familiar São João	P Santos	C Franclim

1			
2			
3			
4			
5	Hospital de Santiago	JF Santos	
6	Hospital da Cruz Vermelha	F Matias	
7	Hospital da Luz	D Ferreira	MB Fonseca
8	Hospital de Faro	J Mimoso	W Santos; J Amando
9	Unidade Local de Saúde do Alto Minho	R Lima	R Lima; CC Dias; C Mateus; V Enes; G Silva
10	Hospital de Braga	A Gaspar	J Oliveira; M Goncalves
11	<b>Romania</b>		
12	<i>NPI</i> : S Balanescu		
13	Spital Judetean de Urgenta	G Stanciulescu	
14	Spital Clinic Judetean Urgenta Arad	D Darabantiu	AM Pop; CD Patrascanu
15	Spital Clinic de Recuperare	D Zdrenghea	I Gusetu
16	Spitalul Judetean Drobeta-Turnu Severin	N Trocan	V Toman; J Cristian
17	Spitalul Clinic de Urgenta Bucuresti	M Dorobantu	O Tautu; I Petre; A Deaconu
18	Spital Clinic Municipal de Urgenta	M C Tomescu	I M Citu
19	Spitalul Universitar de Urgenta Elias	S Huidu	L Ionescu
20	Centru Clinic de Cardiologie	R Musetescu	D Toader
21	Spitalul Judetean de Urgenta 'Sf. Pantelimon' Focsani	C Bengus	M Miron; M Burca; V Ochean
22	Spital Judetean de Urgenta Braila	M Bogdan	L Serban
23	Spitalul Monza Bucuresti	S Balanescu	C L Caldararu; T Cristion-Razvan; A Linte; A Georgescu
24	Spital Clinic de Urgenta Sf. Pantelimon	L Protopopescu	
25	Spitalul Clinic Judetean de Urgenta Sibiu	I Manitiu	M Teodoru; C Zagoni
26	Clinica Polissano	M Vladoianu	O Purcar; R Dobrin
27	Institutul de Boli Cardiovasculare Timisoara	L Petrescu	D Maximov; R Dan; R Nicola
28	<b>Spain</b>		
29			
30			
31			
32			
33			
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			

<i>NPI: AF Ortiz</i>		
Complejo Hospitalario Virgen del Rocio	JN Portero	
Hospital de Baza	MM Robles; G Arquero	
Hospital General de Vic	JS Serrasolsas	RR Fernandez
Hospital Vall D'Hebron	JAB Riu	J Baneras
Complejo Hospitalario Universitario de Santiago	PM Ramos	J Seijas
Hospital General Universitario de Alicante	VIA Esteban	RA Ferrer
Hospital Clinico San Carlos	AF Ortiz	R Guerra; S Mera
Hospital Puerta de Hierro	P Pavia	A Gonzalez; M Cordoba
Hospital del Mar de Barcelona	JB Cortada	P Cabero; C Soleer
Hospital de Bellvitge	AC Filiat	M Nato; O Alegre
Hospital Virgen del Mar de America	JLB Coronado	
Hospital San Pedro de Alcantara	FJF Portales	P Dominguez; S Romani
Hospital Ramón y Cajal	M Sanmartin	LM Rincon; D del Van
Hospital 12 de Octubre	RM Asenjo	
Hospital Virgen de Arrixaca	F Marin Ortuno	E Orenes; M Quintana Giner
Hospital de Lerida	M Pique	M Agusti; L Barta
Hospital Principe de Asturias	A Garcia Lledo	JAS Barrio; FL Bachiller; JG Pérez-Velasco; VP Mir; VB Jimenez; GB Lopez
Hospital Son Llatzer	T Ripoll	Y Gomez
Hospital Univeritario San Cecilio	BG Extremeira; JGS Ramos	E Jimenez; E Garcia; ML Abaraca; A Guarnido; I Merida
<b>Turkey</b>		
<i>NPI: E Bozkurt</i>		
T.C. Sağlık Bakanlığı Yıldırım Beyazıt Üniv. Atatürk	E Bozkurt	H Ayhan

Eğt. Arşt. Hastanesi		
Recep Tayyip Erdoğan Üniv. Tıp Fakültesi	M Bostan	Z Karadag; G Irfanoglu
T.C. Sağlık Bakanlığı Yıldırım Beyazıt Üniv. Dışkapı Eğt. Arşt. Hastanesi	E Yeter	A Nallbani
Mersin Üniversitesi Tıp fakültesi	A Camsari	İT Ozcan
Diyarbakır Eğit. Araş. Hast	R Altindag	S Akkaya; İ Erkek
İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi Yerleşkesi	İ Keles	OO Tok; M Cimci
Hacettepe Üniversitesi Tıp Fakültesi	E Atalar	H Yorgun
Adnan Menderes Üniversitesi Araşt Hastanesi	C Ceyhan	H Gungor
<b>UK</b>		
<i>NPI:</i> K Ray		
Craigavon Area Hospital	A Moriarty	A Mackin; A Mcmullan
Northern General Hospital	R Storey	C Bridge; S Spedding-Dutton; G Sangha; R Ecob
Hairmyres Hospital	B O'Rourke	S Clements; C Malcolson
Monklands Hospital	A Pell	J Anderson
Musgrove Park Hospital, Taunton	D McKenzie; M Dayer	K James; F Venn; P Hill
St George's Hospital NHS Trust Research Centre	R Sharma	D Cole
Papworth Hospital NHS Foundation Trust	S Hoole	R McClean; S Meakins; T McGovern; A Shook; G Charman; S Smith
Barnet General Hospital	A Bakhai	L Lim; S Hoole; S Metherell; Vi Krishnamurthy
Royal Wolverhampton NHS Trust, New Cross Hospital	J Cotton	A Smallwood
<b>North America</b>		
<b>Canada</b>		
<i>NPI:</i> S Goodman		

Clinique Sante Cardio MC	C Constance	M Gauthier; J Piche-Giroux
Vizel Cardiac Research	S Vizel	B Fox
Glanz Medicine Professional Corporation	A Glanz	C Vilag
Hamilton Health Sciences - General Site	A Lamy	P Power; T Rizzo; F Toito
Brampton Research Associates	M Gupta	CD La Cruz; R Kahlon; Y Thevakumaran
St-Jerome Medical Research Inc.	Y Pesant	V Sardin; S Grigorova; M Lambert; YS Laframboise
York PCI Research	W Cantor	K Robbins; N Popel
Lawson Health Research Institute	R Petrella	C Dihel; J Duncan; C Bartol; Z Majeed
Saint John Medical Clinic	R Bessoudo (Marr)	G O'Blenis
Cambridge Cardiac Care Inc.	AS Pandey	M Pandey; S Juranics
Keele Medical Place	A Bell	P Kailey
Yorkview Medical Center	I Teitelbaum	J Teitelbaum; J Dimarino
Viacar Recherche Clinique Inc.	R Chehayeb	P Carmichael
Centre de Sante et de Services Sociaux de Thetford	R Dupuis	F Ouimet; M Couture; B Roberge
<b>USA</b>		
<i>NPI:</i> M Cohen		
Central Bucks Cardiology	JJ Kmetzo	D Taylor; R Riley
Ventura Cardiology Consultants Medical Group	N Mayer	B Mitchell
Atlanta Heart Specialists LLC	N Singh	K Turner
Doylestown Cardiology Specialists-VIAA	R Sangrigoli	L Schwarz; S Martin
Kootenai Heart Clinics LLC	W Bennett	L Passey; A Kavanaugh
Fletcher Allen Health Care	D Schneider	M Rowen; K Begin
Maine Research Associates	R J Weiss	D Murphy; A Gagern
Minneapolis Heart Institute Foundation	M Newell	M Buescher

Heart Center Research LLC	N K Mann	B Lamb
The Miriam Hospital	P Gordon	L Felix; J A Gomes
Heart and Vascular Center of West TN	E Korban	A Harrington
Jackson Cardiology Associates PC	R Mehta	Kristy Watkins
Baylor Research Institute	M McKenzie	R Buckner; IS Mohiuddin
Cardiovascular Specialists of Central Maryland	K Friedman	T Burley
Harbor - UCLA Medical Center	WJ French	CC Morales
Duke	TY Wang	S Decker; R Mehta
North Ohio Research Ltd	W Sheldon	A Bohn; K Humphrey; M Fazio
Clearwater Cardiovascular and Interventional Consultants	JK Amin	M Cameron; L Selker
Heart Care Center	M Baig	C Yough
Virginia Heart	T Haddad	J Jain; D Overbeck
Eastern Maine Medical Center	A Wiseman	A Coombs
Northwest Heart Clinical Research, LLC	A Soni	S Bellini; D Golen
Virginia Cardiovascular Associates	H Taheri	K Morgan
South FL Research Group, LLC	J Roberts	K Shatsky
UNC Heart and Vascular Center	P Kaul	A Que-Xu
UPMC Heart and Vascular Institute - Shadyside	K Tummalapalli	M Travis; A Malecky
South Miami Hospital	J Ghitelman	J Jean-Mary
Cardiology Associates of New Jersey	A Schwarcz	
Long Island Cardiovascular Consultants	R D'Agostino	L Lavelle
CAPRI LLC	R Davidson	S Davidson
Apex Research Institute	J Duffy (Tonkon)	J Dolen; M Gonzalez
Robert Packer Hospital	E Kaluski	C Lanning (Lorraine Barten)

Swedish Medical Center	J Petersen II	
St. Vincent Medical Group	JS Rossi	J Gall
Southern Medical Group, P.A.	W Batchelor	P Knap
<b>South America</b>		
<b>Argentina</b>		
<i>NPI: JLCN Estrada</i>		
Hospital Italiano de Buenos Aires	JLCN Estrada	E Castillo
Fundación Favalaro para la Investigación y la Docencia Médica	EA Duronto	L Arrechavala
Hospital Central de Mendoza	RBS Zarandon	O Caruso; G Segui
Sanatorio El Carmen	EA Falu	MC Iriarte
ICBA - Instituto Cardiovascular de Buenos Aires	MS Trivi	A Navarro
Instituto de Cardiología Juana Francisca Cabral	SM Macin	MJG Salazán; L C Vargas
Sanatorio Profesor Itoiz	CA Rapallo	V Ferreiro; R Santos
Sanatorio Modelo de Quilmes S.A.	AD Hrabar	CM Funosas; A Cappi
Hospital Universitario Austral	HE Fernandez	G Marinsalta; J-M Bonorino
Sanatorio Los Arcos	SM Rahabani	
Sanatorio Mayo Privado S.A.	DJ Anauch	M Barrionuevo
Hospital Español	DL Paolantonio	A R Quiroga; I Gribaudo; G Matkovich
Hospital Privado Centro Médico de Córdoba S.A.	OA Salomone	N Konicoff
<b>Brazil</b>		
<i>NPI: JC Nicolau</i>		
Hospital Santa Isabel	APM Kormann	A Marchi; J Spricigo
Hospital Universitário UFMS	DG da Silva Jr	RM Uehara; R Nakasone
Instituto do Coração de Marília	JC Ferreira	L Silva; D Funai; D Rodrigues



	Braga	
Hospital de Base - FAMERP	LN Maia	RP de Brito; O da Silva Jr; N Goes
<b>Colombia</b>		
<i>NPI:</i> N Jaramillo		
Centro de Investigaciones Clínicas S.A.S.	C Arana	M Ceballos; M Gonzalez; O Sierra
IPS Unidad Cardiologica de Cartagena.	M Herrera	D Perez; M Jazime
Asociación IPS Medicos Internistas de Caldas	DI Molina	H Urrea; JM Patiño; GC Giraldo; I Rodriguez
Centro de Investigaciones Cardiodiagnostico S.A. / Fundación del Caribe para la Investigación Biomedica (Fundacion BIOS)	M Urina	N Ramirez
Centro de medicina del Ejercicio y Rehabilitacion Cardiaca	N Jaramillo	M Toloza; G Rasterepo; RMT Giraldo; V Jaramillo
Clinica Cardiovascular Santa Maria	R Fernandez	E Gonzalez; A Quintero
Instituto del Corazon de Bucaramanga	B Vesga	PS Delgado; DPS Avciniegas; H Hernandez; L Rodriguez
Cardiología Hugo Duque, Centro de Excelencia S.A.S. CHD Cardiology	H Duque	M Zuluaga
IPS Centro Cientifico Asistencial Jose Luis Accini SAS	JL Accini	T Valencia
Centro de diagnostico Cardiológico	F Manzur	D Rosales; D Boneu; F Manzur
Centro de Investigacion Clinica Avanzada y Multidisciplinaria, CICLAM S.A.S.	C Jaramillo	G PG Lopez; ML Jaramillo; C F. Jaramillo; L Velasquez
<b>Mexico</b>		
<i>NPI:</i> FP Padilla		
Unidad Medica de Alta Especialidad; Hospital de Cardiología. Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social	ED y Díaz	
Sitio Dr. Alberto Esteban Bazzoni Ruiz	AB Ruiz	D Monreal; AC Tovar
Cardiosalud	GR Martínez	V Delgado; C Preciado; PS Guzman

Cardioarritmias e Investigacion SC	IR Briones	M Ramos
Consultorio Privado Dr. Padilla	FP Padilla	S Fernandez; VM Delgado; L Ruiz
Hospital General de Puebla "Dr. Eduardo Vázquez Navarro"	JCP Alva	M Macip; SR Pabois
Unidad de Investigacion en Salud	O Fierro Fierro	I Gonzalez; DAS Carreon
<b>Venezuela</b>		
<i>NPI:</i> ML Fariña		
Hospital Universitario de Caracas	N Antepara	A Ruggiero; S Martinez
Hospital Militar "Dr. Carlos Arvelo"	S Tovar	E Moya; L Ramirez; M Wilman
Hospital Universitario "Dr. Angel Larralde"	ML Fariña	
Centro Policlínico La Viña	C Delgado	R Rey
Unidad Cardiológica Clínica IDET. Caracas	Á Avendaño	A Sanchez; J Marin

## APPENDIX II: Study variables and healthcare resource utilization

Variable	Details
<b>Baseline / Enrollment</b>	
Clinic/outpatient center type	University General Hospital (UGH), n = 49; non-UGH, n = 144; Other type of hospital/clinic (CCU/cardiology/cardiovascular/research), n = 137; Private clinic, n = 24; Ambulance, n = 10
Patient characteristics	Gender, age, race (latter if allowed by local regulations)
Place of residence	Rural, metropolitan
Educational level	Measured by years of education due to differences in degree programs across countries
Professional status	Employed, self-employed, unemployed, homemaker, retired, student, sick leave, maternity leave, disability pension
Type of residence	Home, nursing home, etc.
Living arrangement status	Living alone, not living alone
Income	Only in countries where feasible
Health insurance status	Only in countries where feasible
Cardiovascular risk factors	Hypertension, hyperlipidemia, diabetes mellitus, obesity, smoking, family history of CAD
Major bleeding risk factors	History of major bleeding or severe liver disease
History of other CVD	PAD, HF, stroke, TIA, ICD, permanent pacemaker, VTE, valve repair/replacement, AF
Medical history re index MI 1 to 3 y prior	Date of occurrence and management strategy (PCI, CABG or medical)
Antithrombotic medication use	Antiplatelets (incl OTC aspirin), and anticoagulants since last MI; dose, duration, switching, planned/unplanned treatment interruptions and reasons eg, intolerance, hypersensitivity, GI bleeding, other bleeding complications, other GI side effects
Medical conditions that may impact antithrombotic therapy use or study outcomes	History of peptic ulcer, renal-, liver-, disease, and lung-disease, other indices precluding frailty, previous invasive surgical treatment considered relevant by the investigator
Medication use at enrollment	Oral antiplatelets, anticoagulants, antidiabetic drugs, lipid-lowering agents, ACE inhibitors, ARBs, diuretics and $\beta$ -blockers, and antidepressants
Healthcare resource use related to cardiovascular or bleeding conditions during the 6 months preceding enrollment	Medication use, and resource use related to medical visits/procedures/investigations: GP or specialist visit, ER admission, number of event-related hospitalizations and duration of stay, and procedures and interventions performed
Routine physical examination	Heart rate, seated blood pressure, weight, height, waist circumference (if current normal practice)
Laboratory safety measures	Serum creatinine (renal function), lipid profile (total cholesterol, HDL, LDL, triglyceride), hemoglobin and glucose/HbA1c; if available and performed within 3 months prior to the visit or 1 month after

	enrollment
Quality of life evaluation	EuroQoL 5-Dimensions (EQ-5D-3L)
<b>Follow-up</b>	
Clinical events – Primary variable	MI, unstable angina with urgent revascularization, stroke or death (any cause) - Primary
Bleeding events requiring medical attention	<i>TIMI definition:</i> needing intervention (practitioner-guided medical/surgical treatment, including temporary or permanent discontinuation/change in medication/study drug dose), or leading to hospitalization, or prompting evaluation (unscheduled visit to a HCP) and diagnostic testing (laboratory or imaging)
Other events of interest	Including pneumonia and associated death outcome, and macular degeneration
Intercurrent medical procedures and hospitalizations unrelated to predefined events	If hospitalization occurred, patients were asked to confirm the duration and primary cause
Prescription status of antithrombotic medication	Antiplatelets (including OTC aspirin) and anticoagulants, dose, duration, adherence, planned/unplanned treatment interruptions, and reasons for interruptions, eg, intolerance, hypersensitivity, GI bleeding, other bleeding complications, other GI side effects
Other medications	Antidiabetic drugs, lipid-lowering agents, ACE inhibitors, ARBs, diuretics, $\beta$ -blockers, and antidepressants
Quality of life evaluation	EuroQoL 5-Dimensions (EQ-5D)
Healthcare resource use related to cardiovascular or bleeding conditions needing medical attention within 6 months since the last call/visit	<p><u>Patient:</u>  <u>Medication use</u>  <u>Resource use related to medical visits/procedures/investigations:</u> GP or specialist visit, ER admission  <u>Productivity loss:</u> employment status for patient and the primary informal caregiver (latter who stays at home from employment to assist the patient); number of event-related days' sick leave for the patient and/or informal caregiver if either employed/self-employed  <u>Intercurrent medical procedures/hospitalizations:</u> number of hospitalizations, primary cause of and duration of stay, not related to a predefined event  <u>Event treating physician/hospital:</u>  <u>Hospitalization:</u> primary cause, number, and duration of stay where event related including level of care per hospitalization (eg, how many days in ICU, general ward, etc.)  <u>Procedures/interventions</u>  <u>Investigations</u>            Where applicable, in-hospital resource utilization before patient death</p>

ACE, angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; CAD, coronary artery disease; CVD, cardiovascular disease; ER, emergency room; GI, gastrointestinal; GP, general practitioner; HbA1c, glycated hemoglobin; HCP, healthcare professional; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HF, heart failure; ICD, implantable cardioverter defibrillator; ICU, intensive care unit; MI, myocardial infarction; OTC, over the counter; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; TIA, transient ischemic attack; TIMI, 'Thrombolysis In Myocardial Infarction'; VTE, venous thromboembolism